HIMSNews Brief
UPDATE May 23: Two developments have emerged since publication that compound the risk profile materially. Hims & Hers confirmed its customer support system was hacked — introducing regulatory, reputational, and liability exposure for a company handling sensitive patient health data. Simultaneously, Novo Nordisk launched a direct Wegovy subscription plan, creating a first-party competitive threat to the GLP-1 telehealth channel that is HIMS's core growth driver. Together, these events strike at both the operational integrity and the revenue logic of the business. The original article flagged the $350mn debt raise as a leverage risk; the breach adds acute trust risk on top, while Novo Nordisk's direct model threatens to commoditize the exact channel that justified borrowing to scale in the first place. Truist raised its HIMS price target on GLP-1 insights, providing a partial offset, but the market is unmoved — shares are down ~66% from peak. Watch for regulatory action tied to the breach and subscriber retention data in the next earnings print; those two signals will determine whether the GLP-1 thesis survives Novo Nordisk's entry.

Hims & Hers Stock Falls 9% After $350 Million Leveraged Acquisition

Data note: This analysis was written on May 19, 2026 and reflects market conditions at that time. Current price: $33.94. Financial figures and price references may have changed. Run a current analysis →

Hims & Hers raised $350M in debt to buy Eucalyptus and fund an AI push, then lost ~9% in a single session.

Hims & Hers Health, Inc. (HIMS) — stock analysis
The numbers
  • HIMS fell ~9% on May 18, closing at $22.29, after the company announced $350M in new debt and an unpriced AI build-out in the same transaction
  • At 15.3x fwd P/E on $2.4bn TTM revenue, the stock carried a multiple suited to a capital-light domestic platform — not a leveraged acquirer running two simultaneous build-outs
  • Watch: post-deal debt/EBITDA and management's first synergy targets — those two disclosures will determine whether the multiple holds or falls further

What Actually Happened

The debt raise was upsized before landing at $350M — that revision is the first tell. Deals rarely get more expensive in ways that benefit the acquirer. The detail most coverage will miss: Hims & Hers is not funding one bet. It is funding two. The Eucalyptus acquisition and an AI initiative land in the same announcement, backed by the same $350M tranche. Integration costs and AI infrastructure spend will run at the same time. The interest clock starts before either investment has returned a dollar. Against $2.4bn in TTM revenue, this is a significant leverage event, not a line-item footnote.

The Catch

HIMS at 15.3x fwd P/E carried a multiple for a focused domestic telehealth operator with clean books. A leveraged acquisition paired with a simultaneous AI build-out changes that picture. Companies running two expensive programs at once tend to see lower multiples — and the 9% drop may not be the last adjustment. The AI component adds costs before it adds revenue. That cuts into near-term earnings at precisely the moment the balance sheet got heavier.

Bottom Line

Growth investors who owned HIMS for its domestic DTC business now hold a harder story to model than they did 48 hours ago. The $350M debt raise clouds every earnings forecast until management discloses post-deal leverage and synergy targets. At $22.29, the stock price requires clean delivery on two concurrent programs — a higher bar than a single-focus business. Value investors have a cleaner entry once the leverage ratio is public. Until then, the one number that sets the tone: debt/EBITDA after deal close.

For context on how a prior HIMS event moved the stock, see Hims & Hers' weight-loss pivot and 15% swing.

For a full breakdown of Hims & Hers' financials, business model, and competitive position, generate a Basis Report at /stock/hims.

Basis Report does not hold positions in securities discussed. This is not investment advice.

Sources & filings